Skip to main content

Advertisement

SpringerLink
Log in

Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Background

Inflammatory markers are strong prognostic factors for survival in a variety of cancers. This study aimed to investigate the relationships between known inflammatory markers and their ability to predict overall survival (OS) in patients receiving docetaxel therapy.

Methods

Sixty-eight patients with advanced cancer were enrolled in a clinical trial of single agent docetaxel from 2000 to 2002. Inflammation was measured using baseline cytokine concentrations, acute phase reactant proteins and white blood cell counts. The neutrophil/lymphocyte ratio (NLR) and Glasgow Prognostic Score (GPS) were calculated. Associations between inflammatory markers and their predictive value for OS were tested.

Results

The majority of patients had elevated inflammatory markers (50–70%). Strong inter-relationships were observed between the different inflammatory indices. Only NLR and GPS were independently predictive of OS. A combined NLR and GPS score demonstrated 11 month differences in overall OS between patients with normal and elevated inflammatory status. Normalisation of NLR after three doses of chemotherapy was associated with significant improvement in survival.

Conclusion

This study found that NLR predicts the clinical outcomes for patients with advanced cancer treated with docetaxel. The clinical utilisation of NLR should be validated in a larger patient population to confirm its utility.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867

    Article  PubMed  CAS  Google Scholar 

  2. Balkwill F, Mantovani A (2010) Cancer and inflammation: implications for pharmacology and therapeutics. Clin Pharmacol Ther 87:401–406

    Article  PubMed  CAS  Google Scholar 

  3. Anderson GM, Nakada MT, DeWitte M (2004) Tumor necrosis factor-[alpha] in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 4:314–320

    Article  PubMed  CAS  Google Scholar 

  4. Michalaki KS, Charles P, Waxman J (2004) Serum levels of IL-6 and TNF-a correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 91:1227

    Article  CAS  Google Scholar 

  5. Scambia UT, Benedetti Panici P, Foti' E, Martucci R, Gadducci A, Perillo A, Facchini V (1995) Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 71:354–356

    Article  PubMed  CAS  Google Scholar 

  6. Blay J-Y, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani J-M, Moskovtchenko J-F, Philip T, Favrot M (1992) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52:3317–3322

    PubMed  CAS  Google Scholar 

  7. Chung YC, Chang CY (2003) Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83:222–226

    Article  PubMed  Google Scholar 

  8. De Vita F, Romano C, Orditura M, Galizia G, Martinelli E, Lieto E, Catalano G (2001) Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator. J Interferon Cytokine Res 21:45–52

    Article  PubMed  Google Scholar 

  9. Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R (1995) Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 13:575–382

    PubMed  CAS  Google Scholar 

  10. Andrews BEN, Shariat SF, Kim J-H, Wheeler TM, Slawin KM, Lerner SP (2002) Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol 167:1475–1481

    Article  PubMed  Google Scholar 

  11. Ledur AFC, David B, Hamberger C, Cavaillon JM (1995) Variable estimates of cytokine levels produced by commercial ELISA kits: results using international cytokine standards. J Immunol Methods 186:171–179

    Article  PubMed  CAS  Google Scholar 

  12. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan A, Ulrich CM (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27:3437–3444

    Article  PubMed  CAS  Google Scholar 

  13. Polterauer S, Grimm C, Tempfer C, Sliutz G, Speiser P, Reinthaller A, Hefler LA (2007) C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol 107:114–117

    Article  PubMed  CAS  Google Scholar 

  14. Lee JG, Cho BC, Bae MK, Lee CY, Park IK, Kim DJ, Ahn SV, Chung KY (2009) Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer 63:106–110

    Article  PubMed  Google Scholar 

  15. Murri AMA, Bartlett JMS, Canney PA, Doughty JC, Wilson C, McMillan DC (2006) Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 94:227–230

    Article  PubMed  Google Scholar 

  16. Sara R, Gavin WAL, Michael A, John G, Donald CM (2007) Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 109:205–212

    Article  Google Scholar 

  17. Sharma R, Hook J, Kumar M, Gabra H (2008) Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer 44:251–226

    Article  PubMed  Google Scholar 

  18. Kishi Y, Kopetz S, Chun Y, Palavecino M, Abdalla E, Vauthey J-N (2009) Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16:614–622

    Article  PubMed  Google Scholar 

  19. Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, Lodge JPA (2008) Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol (EJSO) 34:55–60

    Article  CAS  Google Scholar 

  20. Gomez D, Farid S, Malik H, Young A, Toogood G, Lodge J, Prasad K (2008) Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 32:1757–1762

    Article  PubMed  CAS  Google Scholar 

  21. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E (2009) Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 137:425–428

    Article  PubMed  Google Scholar 

  22. Nakahara K, Monden Y, Ohno K, Fujii Y, Hashimoto J, Kitagawa Y, Kawashima Y (1987) Importance of biologic status to the postoperative prognosis of patients with stage III nonsmall cell lung cancer. J Surg Oncol 36:155–160

    Article  PubMed  CAS  Google Scholar 

  23. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophil–lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91:181–184

    Article  PubMed  CAS  Google Scholar 

  24. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P (2009) Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 197:466–472

    Article  PubMed  Google Scholar 

  25. Chua WCK, Baracos VE, Clarke SJ (2011) Neutrophil–lymphocyte ratio (NLR) predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 104:1288–1295

    Article  PubMed  CAS  Google Scholar 

  26. Charles KA, Rivory LP, Stockler MR, Beale P, Beith J, Boyer M, Clarke SJ (2006) Predicting the toxicity of weekly docetaxel in advanced cancer. Clin Pharmacokinet 45(6):611–612

    Article  PubMed  CAS  Google Scholar 

  27. Slaviero KA, Clarke SJ, McLachlan AJ, Blair EYL, Rivory LP (2004) Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 57:44–53

    Article  PubMed  CAS  Google Scholar 

  28. Slaviero KA, Read JA, Clarke SJ, Rivory LP (2003) Baseline nutritional assessment in advanced cancer patients receiving palliative chemotherapy. Nutr Cancer 46:148–157

    Article  PubMed  Google Scholar 

  29. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2003) Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 89:1028–1030

    Article  PubMed  CAS  Google Scholar 

  30. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2004) Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 90:1704–1706

    PubMed  CAS  Google Scholar 

  31. Halazun K, Hardy MA, Rana AA, Woodland DC, Luyten EJ, Mahadev S, WItkowski P, Stegel AB, Brown RS, Emond JC (2009) Negative impact of neutrophil lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 250:141–151

    Article  PubMed  Google Scholar 

  32. Alexandre J, Rey E, Girre V, Grabar S, Tran A, Montheil V, Rabillon F, Dieras V, Jullien V, Hacrait P, Pons G, Treluyer JM et al (2007) Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Surg Oncol 18:168–172

    CAS  Google Scholar 

  33. Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR (2006) Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res 12:7492–7497

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank Jenny Peat for assistance with statistical analysis. Wei Chua was supported by an NSW Cancer Institute Fellowship (Australia) and a Pfizer Australia Cancer Research Grant.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Sydney Cancer Centre, Concord Repatriation General Hospital, Hospital Road, Concord, Sydney, NSW, Australia

    Wei Chua & Stephen J. Clarke

  2. Faculty of Medicine, University of Sydney, Sydney, NSW, Australia

    Wei Chua & Stephen J. Clarke

  3. School of Medical Sciences (Pharmacology), Faculty of Medicine, University of Sydney, Sydney, NSW, 2006, Australia

    Kellie A. Charles

  4. Bosch Institute, Sydney, NSW, Australia

    Kellie A. Charles

Authors
  1. Wei Chua
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen J. Clarke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kellie A. Charles
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kellie A. Charles.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chua, W., Clarke, S.J. & Charles, K.A. Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Support Care Cancer 20, 1869–1874 (2012). https://doi.org/10.1007/s00520-011-1289-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-011-1289-3

Keywords

Search

Navigation